Back to Search Start Over

CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV

Authors :
Huajun Zhao
Guan Wang
Chunlai Yin
Ang Lin
Jian Zhang
Ailu Yang
Qiuju Han
Xiao Wang
Yucan Wang
Source :
International Journal of Biological Sciences
Publication Year :
2022
Publisher :
Ivyspring International Publisher, 2022.

Abstract

Chronic Hepatitis B virus (CHB) infection is a global public health problem. Oligodeoxynucleotides (ODNs) containing class C unmethylated cytosine-guanine dinucleotide (CpG-C) motifs may provide potential adjuvants for the immunotherapeutic strategy against CHB, since CpG-C ODNs stimulate both B cell and dendritic cell (DC) activation. However, the efficacy of CpG-C ODN as an anti-HBV vaccine adjuvant remains unclear. In this study, we demonstrated that CpG M362 (CpG-C ODN) as an adjuvant in anti-HBV vaccine (cHBV-vaccine) successfully and safely eliminated the virus in HBV-carrier mice. The cHBV-vaccine enhanced DC maturation both in vivo and in vitro, overcame immune tolerance, and recovered exhausted T cells in HBV-carrier mice. Furthermore, the cHBV-vaccine elicited robust hepatic HBV-specific CD8+ and CD4+ T cell responses, with increased cellular proliferation and IFN-γ secretion. Additionally, the cHBV-vaccine invoked a long-lasting follicular CXCR5+ CD8+ T cell response following HBV re-challenge. Taken together, CpG M362 in combination with rHBVvac cleared persistent HBV and achieved long-term virological control, making it a promising candidate for treating CHB.

Details

ISSN :
14492288
Volume :
18
Database :
OpenAIRE
Journal :
International Journal of Biological Sciences
Accession number :
edsair.doi.dedup.....264c4e251de56d131be39f424c8b7053
Full Text :
https://doi.org/10.7150/ijbs.62424